top
Please input keywords
OK
Database
홍보센터
Contact us
KR
CN
EN
JP
회사소개
회사소개
회사 연혁
핵심인력
기업문화
사회적 책임
인재모집
합작연구개발
Antibody R&D
Project Integrum
Antibody discovery platforms
Pipeline
Clinical pipeline
Preclinical pipeline
RenMice
RenMab
RenLite
RenNano
동물/세포 모델
Pharmacology service
유전자 편집
Collaborations
IR
Stock Information
Financial Reports
Listing Documents
Announcements & Notices
Corporate Governance
Investor Calendar
Email Alert
IR Contact
Home
News events
자료 다운로드
포스터 다운로드
홍보센터
뉴스 및 각종 자료 열람
뉴스
공지사항
웨비나
논문게재실적
자료 다운로드
포스터 다운로드
제품정보 다운로드
2023
SITC 2023: *DM001, a Novel TROP2xEGFR Bispecific ADC, Demonstrates Potent Tumor Growth Inhibition in Preclinical Models and Favorable Safety Profile in Cynomolgus Monkey
2023
SITC 2023: Preclinical Evaluation of Fully Human Bispecific Antibody-drug Candidates Targeting HER3 and the Juxtamembrane Region of MUC1
2023
SITC 2023: *DM005, an EGFR х MET Bispecific Antibody-drug Conjugate With a Novel DNA Topoisomerase I Inhibitor Payload, Showed Robust Anti-tumor Activity in Preclinical Models
2023
SITC 2023: BSA01, a Bispecific Antibody-drug Conjugate Targeting EGFR and Membrane-bound MUC1-C, Exhibits Anti-tumor Efficacy In Vivo Efficacy Against Triple-negative Breast Cancer Xenografts
2023
SITC 2023: BCG022: A HER3×MET Bispecific Antibody-drug Conjugate (BsADC) Targeting Key Mechanisms of Bypass Resistance in Multiple Tumor Types
2023
SITC 2023: A Novel Bispecific Antibody-drug Conjugate Targeting PTK7 and TROP2, BCG033, Demonstrates Preclinical Efficacy Against Triple-negative Breast Cancer Xenografts
2023
SITC 2023: Identification of fully human TCR-mimic antibodies targeting the KRAS G12V/HLA complex generated in HLA-transgenic RenMab mice
2023
SITC 2023: Preclinical Application of a Fully Human TCR-mimic Antibody Developed to Target NY-ESO-1/HLA-A02
2023
SITC 2023: Fc-Competent Fully Human Anti-TIGIT Blocking Monoclonal Antibodies Demonstrated Potent Anti-Tumor Efficacy in Preclinical Models
1
2
3
4
5
…
9
GO